Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI’s: Exploration of efficacy of unselected treatment in a multicenter cohort study

医学 贝伐单抗 培美曲塞 内科学 卡铂 肿瘤科 养生 无进展生存期 阿替唑单抗 化疗 肺癌 队列 癌症 彭布罗利珠单抗 顺铂 免疫疗法
作者
C. Steendam,Sophie M. Ernst,Sushil K. Badrising,Marthe S. Paats,Joachim G.J.V. Aerts,Adrianus J. de Langen,Anne‐Marie C. Dingemans
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:181: 107248-107248 被引量:11
标识
DOI:10.1016/j.lungcan.2023.107248
摘要

Objectives In patients with Epidermal Growth Factor Receptor (EGFR)-mutated non-small cell lung (NSCLC) chemotherapy remains standard of care after progression on EGFR-tyrosine kinase inhibitors (TKIs). With the development of anti-angiogenic agents and immune checkpoint inhibitors the landscape of systemic regimens has changed significantly. This cohort study aims to evaluate the efficacy of chemotherapy regimens after progression on EGFR-TKI in a European population. Material and Methods All consecutive patients treated with chemotherapy after progression on EGFR-TKI for EGFR-mutated NSCLC, were identified in two tertiary centers in the Netherlands. Data on best response, progression free survival (PFS) and overall survival (OS) were extracted from medical records. Results In total, 171 lines of chemotherapy were identified: platinum/pemetrexed (PP, n=95), carboplatin/paclitaxel/bevacizumab/atezolizumab (CPBA, n=32), paclitaxel/bevacizumab (PB, n=36) and carboplatin/paclitaxel/bevacizumab (CPB, n=8). Of the 171 lines, 106 were given as first-line after EGFR-TKI. Median PFS did not differ significantly between the first-line regimens (p=0.50), with the highest PFS in PP (5.2 months [95% CI 4.5-5.9]) and CPBA (5.9 months [95% CI 3.8-80]). The majority of the PB group (n=32) received this regimen in a second- or later line with a median PFS of 4.9 months (95% CI 3.3-6.6). First-line regimens had a median OS of 15.3 months (95% CI 11.6-18.9) with no significant difference between regimens (p=0.85). Conclusion After progression on EGFR-TKI, patients with EGFR-mutated NSCLC show substantial benefit on different chemotherapy regimens. In particular, favorable outcomes were seen in patients treated with PP and CPBA as first-line chemotherapy, and PB in further lines of chemotherapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
41651653发布了新的文献求助10
刚刚
k.o.发布了新的文献求助10
刚刚
wy发布了新的文献求助10
1秒前
飘逸小天鹅完成签到 ,获得积分10
1秒前
1秒前
GIN的应助被胡萝卜卜采纳,获得10
2秒前
2秒前
Wali发布了新的文献求助10
3秒前
GIN的应助被zzk采纳,获得10
3秒前
4秒前
4秒前
天霸完成签到,获得积分20
5秒前
CodeCraft的应助被ZRH采纳,获得10
5秒前
白术发布了新的文献求助10
5秒前
5秒前
5秒前
李茗慧完成签到 ,获得积分10
5秒前
完美世界的应助被悦耳皮带采纳,获得10
6秒前
科研通AI6.3的应助被CYLiu采纳,获得10
7秒前
Rauf发布了新的文献求助10
8秒前
xty发布了新的文献求助10
8秒前
Az驳回了yyds的应助
9秒前
科研通AI6.3的应助被FionaZhang采纳,获得10
9秒前
10秒前
10秒前
yyy完成签到 ,获得积分10
10秒前
YAM完成签到 ,获得积分10
11秒前
luoshiwen发布了新的文献求助10
11秒前
Wali完成签到,获得积分10
11秒前
埃及舞发布了新的文献求助10
11秒前
JamesPei的应助被无溪现龙采纳,获得10
11秒前
乌贼爱吃发布了新的文献求助10
12秒前
12秒前
微信研友发布了新的文献求助10
12秒前
xhj666完成签到,获得积分10
12秒前
13秒前
JJyue发布了新的文献求助50
13秒前
wy完成签到,获得积分10
14秒前
arizaki7发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193348
求助须知:如何正确求助?哪些是违规求助? 9579548
关于积分的说明 21866040
捐赠科研通 7792906
什么是DOI,文献DOI怎么找? 3437242
关于科研通互助平台的介绍 2560702
邀请新用户注册赠送积分活动 2484066